Literature DB >> 19531476

Cytotoxicity mediated by the Fas ligand (FasL)-activated apoptotic pathway in stem cells.

Julia Mazar1, Molly Thomas, Ludmila Bezrukov, Alexander Chanturia, Gulcin Pekkurnaz, Shurong Yin, Sergei A Kuznetsov, Pamela G Robey, Joshua Zimmerberg.   

Abstract

Whereas it is now clear that human bone marrow stromal cells (BMSCs) can be immunosuppressive and escape cytotoxic lymphocytes (CTLs) in vitro and in vivo, the mechanisms of this phenomenon remain controversial. Here, we test the hypothesis that BMSCs suppress immune responses by Fas-mediated apoptosis of activated lymphocytes and find both Fas and FasL expression by primary BMSCs. Jurkat cells or activated lymphocytes were each killed by BMSCs after 72 h of co-incubation. In comparison, the cytotoxic effect of BMSCs on non-activated lymphocytes and on caspase-8(-/-) Jurkat cells was extremely low. Fas/Fc fusion protein strongly inhibited BMSC-induced lymphocyte apoptosis. Although we detected a high level of Fas expression in BMSCs, stimulation of Fas with anti-Fas antibody did not result in the expected BMSC apoptosis, regardless of concentration, suggesting a disruption of the Fas activation pathway. Thus BMSCs may have an endogenous mechanism to evade Fas-mediated apoptosis. Cumulatively, these data provide a parallel between adult stem/progenitor cells and cancer cells, consistent with the idea that stem/progenitor cells can use FasL to prevent lymphocyte attack by inducing lymphocyte apoptosis during the regeneration of injured tissues.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19531476      PMCID: PMC2755926          DOI: 10.1074/jbc.M109.032235

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  Mesenchymal stem cells: a new strategy for immunosuppression?

Authors:  Antonio Uccelli; Vito Pistoia; Lorenzo Moretta
Journal:  Trends Immunol       Date:  2007-04-02       Impact factor: 16.687

2.  Human mesenchymal stem cells promote survival of T cells in a quiescent state.

Authors:  Federica Benvenuto; Stefania Ferrari; Ezio Gerdoni; Francesca Gualandi; Francesco Frassoni; Vito Pistoia; Gianluigi Mancardi; Antonio Uccelli
Journal:  Stem Cells       Date:  2007-03-29       Impact factor: 6.277

3.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

4.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Authors:  Amelia Bartholomew; Cord Sturgeon; Mandy Siatskas; Karen Ferrer; Kevin McIntosh; Sheila Patil; Wayne Hardy; Steve Devine; David Ucker; Robert Deans; Annemarie Moseley; Ronald Hoffman
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

Review 5.  The role of Fas ligand in immune privilege.

Authors:  D R Green; T A Ferguson
Journal:  Nat Rev Mol Cell Biol       Date:  2001-12       Impact factor: 94.444

6.  Fas ligand (CD95L) protects neurons against perforin-mediated T lymphocyte cytotoxicity.

Authors:  I Medana; Z Li; A Flügel; J Tschopp; H Wekerle; H Neumann
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

7.  Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.

Authors:  Matus Studeny; Frank C Marini; Richard E Champlin; Claudia Zompetta; Isaiah J Fidler; Michael Andreeff
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

8.  Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype.

Authors:  Seung Tae Lee; Joon Ho Jang; June-Won Cheong; Jin Seok Kim; Ho-Young Maemg; Jee Sook Hahn; Yun Woong Ko; Yoo Hong Min
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

Review 9.  The use of adult stem cells in rebuilding the human face.

Authors:  Pamela Gehron Robey; Paolo Bianco
Journal:  J Am Dent Assoc       Date:  2006-07       Impact factor: 3.634

10.  Mesenchymal stem cells avoid allogeneic rejection.

Authors:  Jennifer M Ryan; Frank P Barry; J Mary Murphy; Bernard P Mahon
Journal:  J Inflamm (Lond)       Date:  2005-07-26       Impact factor: 4.981

View more
  22 in total

1.  Mesenchymal stem cells control alloreactive CD8(+) CD28(-) T cells.

Authors:  A U Engela; C C Baan; N H R Litjens; M Franquesa; M G H Betjes; W Weimar; M J Hoogduijn
Journal:  Clin Exp Immunol       Date:  2013-12       Impact factor: 4.330

2.  Proteomic Profiling of Native Unpassaged and Culture-Expanded Mesenchymal Stromal Cells (MSC).

Authors:  Erika Moravcikova; E Michael Meyer; Mirko Corselli; Vera S Donnenberg; Albert D Donnenberg
Journal:  Cytometry A       Date:  2018-09-13       Impact factor: 4.355

3.  Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis.

Authors:  Kentaro Akiyama; Chider Chen; DanDan Wang; Xingtian Xu; Cunye Qu; Takayoshi Yamaza; Tao Cai; WanJun Chen; Lingyun Sun; Songtao Shi
Journal:  Cell Stem Cell       Date:  2012-04-26       Impact factor: 24.633

4.  Production of reactive oxygen species by multipotent stromal cells/mesenchymal stem cells upon exposure to fas ligand.

Authors:  Melanie Rodrigues; Omari Turner; Donna Stolz; Linda G Griffith; Alan Wells
Journal:  Cell Transplant       Date:  2012-04-17       Impact factor: 4.064

5.  Fas ligand regulates the immunomodulatory properties of dental pulp stem cells.

Authors:  Y Zhao; L Wang; Y Jin; S Shi
Journal:  J Dent Res       Date:  2012-08-17       Impact factor: 6.116

6.  Third-party mesenchymal stem cells improved human islet transplantation in a humanized diabetic mouse model.

Authors:  Hao Wu; Di Wen; Ram I Mahato
Journal:  Mol Ther       Date:  2013-06-14       Impact factor: 11.454

Review 7.  Immunological barriers to stem-cell based cardiac repair.

Authors:  Zaruhi Karabekian; Nikki Gillum Posnack; Narine Sarvazyan
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

8.  Bone marrow stem cell derived paracrine factors for regenerative medicine: current perspectives and therapeutic potential.

Authors:  Tom J Burdon; Arghya Paul; Nicolas Noiseux; Satya Prakash; Dominique Shum-Tim
Journal:  Bone Marrow Res       Date:  2010-12-06

Review 9.  How stem cells speak with host immune cells in inflammatory brain diseases.

Authors:  Stefano Pluchino; Chiara Cossetti
Journal:  Glia       Date:  2013-04-30       Impact factor: 7.452

10.  Low FasL levels promote proliferation of human bone marrow-derived mesenchymal stem cells, higher levels inhibit their differentiation into adipocytes.

Authors:  M R Rippo; L Babini; F Prattichizzo; L Graciotti; G Fulgenzi; F Tomassoni Ardori; F Olivieri; G Borghetti; S Cinti; A Poloni; F Fazioli; A D Procopio
Journal:  Cell Death Dis       Date:  2013-04-18       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.